oxidopamine has been researched along with Degenerative Diseases, Central Nervous System in 77 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Posttreatment with paeonol also reduced inflammatory responses in LPS-activated microglia and increased cell viability in LPS-treated microglia culture medium-treated neurons." | 5.38 | Paeonol attenuates microglia-mediated inflammation and oxidative stress-induced neurotoxicity in rat primary microglia and cortical neurons. ( Hsu, YY; Lo, YC; Shih, YT; Tseng, YT, 2012) |
| "Studies have shown that hydrogen sulfide (H2S) exerts a neuroprotective effect and may have a therapeutic value for treating neurodegenerative diseases including Parkinson's disease." | 3.88 | Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease. ( Babayan-Tazehkand, A; Haghdoost-Yazdi, H; Rastgoo, N; Sarbazi-Golezari, A; Sarookhani, MR, 2018) |
| "Chlorogenic acid (CGA) is a polyphenolic substance derived from various medicinal plants." | 1.91 | Chlorogenic acid delays the progression of Parkinson's disease via autophagy induction in ( He, CL; Long, T; Pan, R; Qin, DL; Qiu, WQ; Tang, Y; Teng, JF; Wu, AG; Wu, JM; Yu, CL; Yu, L; Zhou, XG, 2023) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative diseases that are presently incurable." | 1.91 | Small-Molecule Cdc25A Inhibitors Protect Neuronal Cells from Death Evoked by NGF Deprivation and 6-Hydroxydopamine. ( Banerji, B; Biswas, SC; Das, AK; Pramanik, SK; Sanphui, P, 2023) |
| "Parkinson's disease is a neurodegenerative disease characterized by progressive dopaminergic neuronal loss." | 1.72 | Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease. ( Choe, HK; Choe, Y; Choi, JW; Choi, M; Jang, S; Kim, D; Kim, J; Kim, K; Moon, C; Park, I; Park, SH; Sun, W, 2022) |
| "Parkinson's disease is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra with no effective cure available." | 1.72 | MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson's disease. ( Abreu, R; Barão, M; Bernardino, L; Cristóvão, AC; Esteves, M; Fernandes, H; Ferreira, L; Ferreira, R; Martins, PAT; Saraiva, C; Serra-Almeida, C, 2022) |
| "Fluconazole was able to prevent neurite retraction and cell death in in vitro and in vivo models of toxicity." | 1.72 | Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor. ( Bachani, M; Johnson, TP; Lee, MH; Malik, N; Nath, A; Ruffin, A; Steiner, JP; Toodle, V; Vivekanandhan, S; Wang, T, 2022) |
| "Parkinson's disease was induced by administration of (20 µg/5 µl at the rate of 1 µl/min) 6-OHDA and exercise training was given to mice by motorized rodent treadmill for a period of 14 days after the confirmation of PD." | 1.72 | Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6. ( Fu, J; Guo, J; Tripathi, A; Yang, J, 2022) |
| "Ramelteon is an oral hypnotic agent that specifically targets the receptors of the suprachiasmatic nucleus in the human hypothalamus." | 1.62 | The protective effects of Ramelteon against 6-OHDA-induced cellular senescence in human SH-SY5Y neuronal cells. ( Cai, M; Gu, X; Han, F; Han, L; Liu, D; Liu, W; Ma, Q, 2021) |
| "Parkinson's disease is a neurodegenerative disease characterized by a loss of dopaminergic substantia nigra neurons and depletion of dopamine." | 1.56 | mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease. ( Abd-Elrahman, KS; Bureau, SC; Derksen, A; Dwyer, Z; Farmer, K; Ferguson, SSG; Fortin, T; Hayley, S; Prowse, NA; Rowe, EM; Rudyk, CA; Thompson, AM, 2020) |
| " Importantly, CVL-751 efficacy is observed with less of the concomitant dyskinesia side effect associated with L-DOPA treatment." | 1.56 | D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects. ( Brevard, J; Fonseca, KR; Gray, DL; Kozak, R; Popiolek, M; Trapa, P; Young, D, 2020) |
| " Quercetin (QC) in combination with piperine (bioenhancer) acts as potential antioxidant, anti-inflammatory and neuroprotective against 6-OHDA rat model of PD." | 1.48 | Piperine in combination with quercetin halt 6-OHDA induced neurodegeneration in experimental rats: Biochemical and neurochemical evidences. ( Kumar, P; Singh, S, 2018) |
| "To explore a novel therapy against Parkinson's disease through enhancement of α7 nicotinic acetylcholine receptor (nAChR), we evaluated the neuroprotective effects of 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (DMXBA; GTS-21), a functionally selective α7 nAChR agonist, in a rat 6-hydroxydopamine (6-OHDA)-induced hemiparkinsonian model." | 1.39 | 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats. ( Hisahara, S; Kawamata, J; Kem, W; Kitamura, Y; Matsumura, A; Matsushita, T; Shimohama, S; Suzuki, S; Takata, K, 2013) |
| "Posttreatment with paeonol also reduced inflammatory responses in LPS-activated microglia and increased cell viability in LPS-treated microglia culture medium-treated neurons." | 1.38 | Paeonol attenuates microglia-mediated inflammation and oxidative stress-induced neurotoxicity in rat primary microglia and cortical neurons. ( Hsu, YY; Lo, YC; Shih, YT; Tseng, YT, 2012) |
| "Studies on Parkinson's disease patients and dopamine-depleted animals indicate that dopaminergic neurons in the retina degenerate due to the genetic and environmental factors that cause dopaminergic neuron loss in the substantia nigra." | 1.37 | Minor retinal degeneration in Parkinson's disease. ( Huang, YM; Yin, ZQ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.30) | 18.2507 |
| 2000's | 14 (18.18) | 29.6817 |
| 2010's | 32 (41.56) | 24.3611 |
| 2020's | 30 (38.96) | 2.80 |
| Authors | Studies |
|---|---|
| He, CL | 1 |
| Tang, Y | 1 |
| Wu, JM | 1 |
| Long, T | 1 |
| Yu, L | 1 |
| Teng, JF | 1 |
| Qiu, WQ | 1 |
| Pan, R | 1 |
| Yu, CL | 1 |
| Qin, DL | 1 |
| Wu, AG | 1 |
| Zhou, XG | 1 |
| Mazzocchi, M | 1 |
| Goulding, SR | 1 |
| Morales-Prieto, N | 1 |
| Foley, T | 1 |
| Collins, LM | 1 |
| Sullivan, AM | 1 |
| O'Keeffe, GW | 1 |
| Yu, S | 1 |
| Peng, HR | 1 |
| Zhang, YK | 1 |
| Yin, YQ | 1 |
| Zhou, JW | 1 |
| Kim, J | 2 |
| Park, I | 1 |
| Jang, S | 2 |
| Choi, M | 2 |
| Kim, D | 1 |
| Sun, W | 1 |
| Choe, Y | 2 |
| Choi, JW | 1 |
| Moon, C | 1 |
| Park, SH | 1 |
| Choe, HK | 2 |
| Kim, K | 2 |
| Luo, Y | 1 |
| Zhou, S | 1 |
| Takeda, R | 1 |
| Okazaki, K | 1 |
| Sekita, M | 1 |
| Sakamoto, K | 1 |
| Jalgaonkar, S | 1 |
| Gajbhiye, S | 1 |
| Sayyed, M | 1 |
| Tripathi, R | 1 |
| Khatri, N | 1 |
| Parmar, U | 1 |
| Shankar, A | 1 |
| Huang, Z | 1 |
| Han, J | 1 |
| Wu, P | 1 |
| Wu, C | 1 |
| Fan, Y | 1 |
| Zhao, L | 1 |
| Hao, X | 1 |
| Chen, D | 1 |
| Zhu, M | 1 |
| Esteves, M | 1 |
| Abreu, R | 1 |
| Fernandes, H | 1 |
| Serra-Almeida, C | 1 |
| Martins, PAT | 1 |
| Barão, M | 1 |
| Cristóvão, AC | 1 |
| Saraiva, C | 1 |
| Ferreira, R | 1 |
| Ferreira, L | 1 |
| Bernardino, L | 1 |
| Ni, W | 1 |
| Zhou, J | 1 |
| Ling, Y | 1 |
| Lu, X | 1 |
| Niu, D | 1 |
| Zeng, Y | 1 |
| Qiu, Y | 1 |
| Si, Y | 1 |
| Wang, J | 1 |
| Zhang, W | 1 |
| Wang, Z | 1 |
| Hu, J | 1 |
| Toodle, V | 1 |
| Lee, MH | 1 |
| Bachani, M | 1 |
| Ruffin, A | 1 |
| Vivekanandhan, S | 1 |
| Malik, N | 1 |
| Wang, T | 1 |
| Johnson, TP | 1 |
| Nath, A | 1 |
| Steiner, JP | 1 |
| Alarcon-Gil, J | 1 |
| Sierra-Magro, A | 1 |
| Morales-Garcia, JA | 1 |
| Sanz-SanCristobal, M | 1 |
| Alonso-Gil, S | 1 |
| Cortes-Canteli, M | 1 |
| Niso-Santano, M | 1 |
| Martínez-Chacón, G | 1 |
| Fuentes, JM | 1 |
| Santos, A | 1 |
| Perez-Castillo, A | 1 |
| Lei, T | 1 |
| Xiao, Z | 1 |
| Zhang, X | 2 |
| Cai, S | 1 |
| Bi, W | 1 |
| Yang, Y | 1 |
| Wang, D | 1 |
| Li, Q | 1 |
| Du, H | 1 |
| Lee, DW | 1 |
| Ryu, YK | 1 |
| Chang, DH | 1 |
| Park, HY | 1 |
| Go, J | 1 |
| Maeng, SY | 1 |
| Hwang, DY | 1 |
| Kim, BC | 1 |
| Lee, CH | 1 |
| Kim, KS | 1 |
| Guo, SY | 1 |
| Guan, RX | 1 |
| Chi, XD | 1 |
| Sui, AR | 1 |
| Zhao, W | 1 |
| Supratik, K | 1 |
| Yang, JY | 1 |
| Zhao, J | 1 |
| Li, S | 1 |
| Guo, J | 3 |
| Yang, J | 3 |
| Fu, J | 3 |
| Tripathi, A | 3 |
| Cesaroni, V | 2 |
| Blandini, F | 4 |
| Cerri, S | 3 |
| Ma, C | 1 |
| Feng, Y | 1 |
| Li, X | 1 |
| Sun, L | 1 |
| He, Z | 1 |
| Gan, J | 1 |
| He, M | 1 |
| Chen, X | 1 |
| Pramanik, SK | 1 |
| Sanphui, P | 1 |
| Das, AK | 1 |
| Banerji, B | 1 |
| Biswas, SC | 1 |
| Mahoney-Rafferty, EC | 1 |
| Tucker, HR | 1 |
| Akhtar, K | 1 |
| Herlihy, R | 1 |
| Audil, A | 1 |
| Shah, D | 1 |
| Gupta, M | 1 |
| Kochman, EM | 1 |
| Feustel, PJ | 1 |
| Molho, ES | 1 |
| Pilitsis, JG | 1 |
| Shin, DS | 1 |
| Chen, XY | 1 |
| Feng, SN | 1 |
| Bao, Y | 1 |
| Zhou, YX | 1 |
| Ba, F | 1 |
| Silva da Fonsêca, V | 1 |
| Goncalves, VC | 1 |
| Augusto Izidoro, M | 1 |
| Guimarães de Almeida, AC | 1 |
| Luiz Affonso Fonseca, F | 1 |
| Alexandre Scorza, F | 1 |
| Finsterer, J | 1 |
| Scorza, CA | 1 |
| Liu, W | 2 |
| Zhang, R | 1 |
| Feng, H | 1 |
| Luo, J | 1 |
| Zhu, H | 1 |
| Morton, KS | 1 |
| Hartman, JH | 1 |
| Heffernan, N | 1 |
| Ryde, IT | 1 |
| Kenny-Ganzert, IW | 1 |
| Meng, L | 1 |
| Sherwood, DR | 1 |
| Meyer, JN | 1 |
| Mei, M | 1 |
| Zhou, Y | 1 |
| Liu, M | 1 |
| Zhao, F | 1 |
| Wang, C | 1 |
| Ding, J | 1 |
| Lu, M | 1 |
| Hu, G | 1 |
| Farmer, K | 1 |
| Abd-Elrahman, KS | 1 |
| Derksen, A | 1 |
| Rowe, EM | 1 |
| Thompson, AM | 1 |
| Rudyk, CA | 1 |
| Prowse, NA | 1 |
| Dwyer, Z | 1 |
| Bureau, SC | 1 |
| Fortin, T | 1 |
| Ferguson, SSG | 1 |
| Hayley, S | 1 |
| Young, D | 1 |
| Popiolek, M | 1 |
| Trapa, P | 1 |
| Fonseca, KR | 1 |
| Brevard, J | 1 |
| Gray, DL | 1 |
| Kozak, R | 1 |
| Rosa, I | 1 |
| Di Censo, D | 1 |
| Ranieri, B | 1 |
| Di Giovanni, G | 1 |
| Scarnati, E | 1 |
| Alecci, M | 1 |
| Galante, A | 1 |
| Florio, TM | 1 |
| Zygogianni, O | 1 |
| Kouroupi, G | 1 |
| Taoufik, E | 1 |
| Matsas, R | 1 |
| Falquetto, B | 1 |
| Thieme, K | 1 |
| Malta, MB | 1 |
| E Rocha, KC | 1 |
| Tuppy, M | 1 |
| Potje, SR | 1 |
| Antoniali, C | 1 |
| Rodrigues, AC | 1 |
| Munhoz, CD | 1 |
| Moreira, TS | 1 |
| Takakura, AC | 1 |
| Liu, D | 1 |
| Gu, X | 1 |
| Han, F | 1 |
| Cai, M | 1 |
| Han, L | 1 |
| Ma, Q | 1 |
| Ghasemloo, E | 1 |
| Mostafavi, H | 1 |
| Hosseini, M | 1 |
| Forouzandeh, M | 1 |
| Eskandari, M | 1 |
| Mousavi, SS | 1 |
| Singh, S | 2 |
| Kumar, P | 1 |
| Sarookhani, MR | 1 |
| Haghdoost-Yazdi, H | 1 |
| Sarbazi-Golezari, A | 1 |
| Babayan-Tazehkand, A | 1 |
| Rastgoo, N | 1 |
| Mercado, G | 1 |
| Castillo, V | 1 |
| Soto, P | 1 |
| López, N | 1 |
| Axten, JM | 1 |
| Sardi, SP | 1 |
| Hoozemans, JJM | 1 |
| Hetz, C | 1 |
| Leino, S | 1 |
| Koski, SK | 1 |
| Hänninen, R | 1 |
| Tapanainen, T | 1 |
| Rannanpää, S | 1 |
| Salminen, O | 1 |
| Kamireddy, K | 1 |
| Chinnu, S | 2 |
| Priyanka, PS | 1 |
| Rajini, PS | 2 |
| Giridhar, P | 1 |
| Chung, S | 1 |
| Son, GH | 1 |
| Rhee, K | 1 |
| Rentsch, P | 1 |
| Stayte, S | 1 |
| Morris, GP | 1 |
| Vissel, B | 1 |
| Herzog, CD | 1 |
| Brown, L | 1 |
| Kruegel, BR | 1 |
| Wilson, A | 1 |
| Tansey, MG | 1 |
| Gage, FH | 1 |
| Johnson, EM | 1 |
| Bartus, RT | 1 |
| Diana, V | 1 |
| Libani, IV | 1 |
| Armentero, MT | 1 |
| Lucignani, G | 1 |
| Silani, V | 1 |
| Cova, L | 1 |
| Ottobrini, L | 1 |
| Suzuki, H | 1 |
| Ono, K | 1 |
| Sawada, M | 1 |
| Gombash, SE | 1 |
| Manfredsson, FP | 1 |
| Mandel, RJ | 1 |
| Collier, TJ | 3 |
| Fischer, DL | 1 |
| Kemp, CJ | 1 |
| Kuhn, NM | 1 |
| Wohlgenant, SL | 1 |
| Fleming, SM | 1 |
| Sortwell, CE | 2 |
| Paumier, KL | 1 |
| Madhavan, L | 2 |
| Terpstra, B | 1 |
| Celano, SL | 1 |
| Green, JJ | 1 |
| Imus, NM | 1 |
| Marckini, N | 1 |
| Daley, B | 1 |
| Steece-Collier, K | 2 |
| Yurek, DM | 1 |
| Hasselrot, U | 1 |
| Cass, WA | 1 |
| Sesenoglu-Laird, O | 1 |
| Padegimas, L | 1 |
| Cooper, MJ | 1 |
| Iqbal, S | 1 |
| Howard, S | 1 |
| LoGrasso, PV | 1 |
| Shashikumar, S | 1 |
| Pradeep, H | 1 |
| Rajanikant, GK | 1 |
| Daley, BF | 1 |
| Davidson, BL | 1 |
| Boudreau, RL | 1 |
| Lipton, JW | 1 |
| Cole-Strauss, A | 1 |
| Johnson, AM | 1 |
| Grant, LM | 1 |
| Schallert, T | 1 |
| Ciucci, MR | 1 |
| Pellegrini, C | 1 |
| Fornai, M | 1 |
| Colucci, R | 1 |
| Tirotta, E | 1 |
| Levandis, G | 1 |
| Segnani, C | 1 |
| Ippolito, C | 1 |
| Bernardini, N | 1 |
| Cseri, K | 1 |
| Blandizzi, C | 1 |
| Haskó, G | 1 |
| Antonioli, L | 1 |
| de Oliveira, PA | 1 |
| Ben, J | 1 |
| Matheus, FC | 1 |
| Schwarzbold, ML | 1 |
| Moreira, ELG | 1 |
| Rial, D | 1 |
| Walz, R | 1 |
| Prediger, RD | 1 |
| Locke, CJ | 1 |
| Fox, SA | 1 |
| Caldwell, GA | 1 |
| Caldwell, KA | 1 |
| Pienaar, IS | 1 |
| Kellaway, LA | 1 |
| Russell, VA | 1 |
| Smith, AD | 1 |
| Stein, DJ | 1 |
| Zigmond, MJ | 1 |
| Daniels, WM | 1 |
| Shimohama, S | 3 |
| Ugrumov, MV | 1 |
| Pérez, V | 1 |
| Marin, C | 1 |
| Rubio, A | 1 |
| Aguilar, E | 1 |
| Barbanoj, M | 1 |
| Kulisevsky, J | 1 |
| Huang, YM | 1 |
| Yin, ZQ | 1 |
| Massie, A | 1 |
| Schallier, A | 1 |
| Kim, SW | 1 |
| Fernando, R | 1 |
| Kobayashi, S | 1 |
| Beck, H | 1 |
| De Bundel, D | 1 |
| Vermoesen, K | 1 |
| Bannai, S | 1 |
| Smolders, I | 1 |
| Conrad, M | 1 |
| Plesnila, N | 1 |
| Sato, H | 1 |
| Michotte, Y | 1 |
| Hu, X | 1 |
| Weng, Z | 1 |
| Chu, CT | 1 |
| Zhang, L | 1 |
| Cao, G | 1 |
| Gao, Y | 1 |
| Signore, A | 1 |
| Zhu, J | 1 |
| Hastings, T | 1 |
| Greenamyre, JT | 1 |
| Chen, J | 1 |
| Decressac, M | 1 |
| Pain, S | 1 |
| Chabeauti, PY | 1 |
| Frangeul, L | 1 |
| Thiriet, N | 1 |
| Herzog, H | 1 |
| Vergote, J | 1 |
| Chalon, S | 1 |
| Jaber, M | 1 |
| Gaillard, A | 1 |
| Mencarelli, C | 1 |
| Bode, GH | 1 |
| Vlamings, R | 1 |
| Janssen, ML | 1 |
| Losen, M | 1 |
| De Baets, MH | 1 |
| Steinbusch, HW | 1 |
| Temel, Y | 1 |
| Martinez-Martinez, P | 1 |
| Tseng, YT | 1 |
| Hsu, YY | 1 |
| Shih, YT | 1 |
| Lo, YC | 1 |
| Kim, SS | 1 |
| Lim, J | 1 |
| Bang, Y | 1 |
| Gal, J | 1 |
| Lee, SU | 1 |
| Cho, YC | 1 |
| Yoon, G | 1 |
| Kang, BY | 1 |
| Cheon, SH | 1 |
| Choi, HJ | 1 |
| Borah, A | 1 |
| Mohanakumar, KP | 1 |
| Kim, Y | 1 |
| Li, E | 1 |
| Park, S | 1 |
| Yin, LH | 1 |
| Shen, H | 1 |
| Diaz-Ruiz, O | 1 |
| Bäckman, CM | 1 |
| Bae, E | 1 |
| Yu, SJ | 1 |
| Wang, Y | 1 |
| Lin, HY | 1 |
| Yeh, WL | 1 |
| Huang, BR | 1 |
| Lin, C | 1 |
| Lai, CH | 1 |
| Lin, H | 1 |
| Lu, DY | 1 |
| Suzuki, S | 1 |
| Kawamata, J | 1 |
| Matsushita, T | 1 |
| Matsumura, A | 1 |
| Hisahara, S | 1 |
| Takata, K | 2 |
| Kitamura, Y | 2 |
| Kem, W | 1 |
| Cutillas, B | 1 |
| Ambrosio, S | 1 |
| Unzeta, M | 1 |
| Youdim, MB | 3 |
| Stephenson, G | 1 |
| Ben Shachar, D | 1 |
| Das, T | 1 |
| Ravindran, A | 1 |
| Chaturvedi, RK | 1 |
| Shukla, Y | 1 |
| Agarwal, AK | 1 |
| Dikshit, M | 1 |
| Inden, M | 1 |
| Kondo, J | 1 |
| Hayashi, K | 1 |
| Yanagida, T | 1 |
| Tsuchiya, D | 1 |
| Yanagisawa, D | 1 |
| Nishimura, K | 1 |
| Taniguchi, T | 1 |
| Sugimoto, H | 1 |
| Akaike, A | 1 |
| Zheng, H | 1 |
| Gal, S | 1 |
| Weiner, LM | 1 |
| Bar-Am, O | 2 |
| Warshawsky, A | 1 |
| Fridkin, M | 1 |
| Kupershmidt, L | 1 |
| Amit, T | 1 |
| Blumenfeld, Z | 1 |
| Cadet, JL | 1 |
| Brannock, C | 1 |
| Heumann, R | 1 |
| Goemans, C | 1 |
| Bartsch, D | 1 |
| Lingenhöhl, K | 1 |
| Waldmeier, PC | 1 |
| Hengerer, B | 1 |
| Allegrini, PR | 1 |
| Schellander, K | 1 |
| Wagner, EF | 1 |
| Arendt, T | 1 |
| Kamdem, RH | 1 |
| Obst-Pernberg, K | 1 |
| Narz, F | 1 |
| Wahle, P | 1 |
| Berns, H | 1 |
| Ghorayeb, I | 1 |
| Puschban, Z | 1 |
| Fernagut, PO | 1 |
| Scherfler, C | 1 |
| Rouland, R | 1 |
| Wenning, GK | 1 |
| Tison, F | 1 |
| Mihm, MJ | 1 |
| Schanbacher, BL | 1 |
| Wallace, BL | 1 |
| Wallace, LJ | 1 |
| Uretsky, NJ | 1 |
| Bauer, JA | 1 |
5 reviews available for oxidopamine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Changes in Rat 50-kHz Ultrasonic Vocalizations During Dopamine Denervation and Aging: Relevance to Neurodegeneration.
Topics: Adrenergic Agents; Aging; Animals; Denervation; Dopamine; Neurodegenerative Diseases; Oxidopamine; P | 2015 |
Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Drug Synergism; Galantamine | 2009 |
[Synthesis of monoamines by non-monoaminergic neurons: illusion or reality?].
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain; Corpus Striatum; Dopamine; Humans; Hypothalamu | 2009 |
Free radicals and the pathobiology of brain dopamine systems.
Topics: Animals; Brain; Dopamine; Free Radicals; Humans; Methamphetamine; N-Methyl-3,4-methylenedioxyampheta | 1998 |
72 other studies available for oxidopamine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Chlorogenic acid delays the progression of Parkinson's disease via autophagy induction in
Topics: Animals; Animals, Genetically Modified; Autophagy; Caenorhabditis elegans; Chlorogenic Acid; Disease | 2023 |
Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Histone Deacetylase Inhibito | 2022 |
Central dopaminergic control of cell proliferation in the colonic epithelium.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Epithelium; Mic | 2022 |
Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease.
Topics: Animals; Humans; Isoquinolines; Mice; Mood Disorders; Neurodegenerative Diseases; Nuclear Receptor S | 2022 |
Protective Effect of Amber Extract on Human Dopaminergic Cells against 6-Hydroxydopamine-Induced Neurotoxicity.
Topics: Amber; Dopaminergic Neurons; Humans; Neurodegenerative Diseases; Oxidopamine; Plant Extracts | 2022 |
S-adenosyl methionine improves motor co-ordination with reduced oxidative stress, dopaminergic neuronal loss, and DNA methylation in the brain striatum of 6-hydroxydopamine-induced neurodegeneration in rats.
Topics: Animals; Antioxidants; Brain; Disease Models, Animal; DNA Methylation; Dopamine; Glutathione; Methio | 2023 |
Sorting Nexin 5 Plays an Important Role in Promoting Ferroptosis in Parkinson's Disease.
Topics: Animals; Ferroptosis; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Rats; Sorting Nexi | 2022 |
MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Extracellular Vesicles; Mice; MicroRNAs; Neur | 2022 |
Neural stem cell secretome exerts a protective effect on damaged neuron mitochondria in Parkinson's disease model.
Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Dopaminergic Neurons; Mitochondria; Neural | 2022 |
Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor.
Topics: Animals; Antifungal Agents; D-Aspartic Acid; Fluconazole; Insulins; Neurodegenerative Diseases; Neur | 2022 |
Neuroprotective and Anti-Inflammatory Effects of Linoleic Acid in Models of Parkinson's Disease: The Implication of Lipid Droplets and Lipophagy.
Topics: Animals; Autophagy; Cell Line, Tumor; Humans; Linoleic Acid; Lipid Droplets; Mice; Neuroblastoma; Ne | 2022 |
Human gingival mesenchymal stem cells improve movement disorders and tyrosine hydroxylase neuronal damage in Parkinson disease rats.
Topics: Animals; Calcium; Gingiva; Glial Fibrillary Acidic Protein; Humans; Mesenchymal Stem Cells; Mice; Mi | 2022 |
Topics: Animals; Base Composition; Clostridiales; Dextroamphetamine; Disease Models, Animal; Dopaminergic Ne | 2022 |
Scorpion venom heat-resistant synthetic peptide protects dopamine neurons against 6-hydroxydopamine neurotoxicity in C. elegans.
Topics: Animals; Caenorhabditis elegans; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Hot Tempera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Potential Therapeutic Effects of Policosanol from Insect Wax on Caenorhabditis elegans Models of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Disease Models, Ani | 2023 |
Small-Molecule Cdc25A Inhibitors Protect Neuronal Cells from Death Evoked by NGF Deprivation and 6-Hydroxydopamine.
Topics: Alzheimer Disease; cdc25 Phosphatases; Dopamine; Humans; Nerve Growth Factor; Neurodegenerative Dise | 2023 |
Assessing the Location, Relative Expression and Subclass of Dopamine Receptors in the Cerebellum of Hemi-Parkinsonian Rats.
Topics: Animals; Cerebellum; Disease Models, Animal; Dopamine; Humans; Male; Neurodegenerative Diseases; Oxi | 2023 |
Identification of Clec7a as the therapeutic target of rTMS in alleviating Parkinson's disease: targeting neuroinflammation.
Topics: Animals; Dopaminergic Neurons; Neurodegenerative Diseases; Neuroinflammatory Diseases; Oxidopamine; | 2023 |
Parkinson's Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model.
Topics: Alanine; Animals; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Quality of Life; Rats | 2023 |
Increased expression of Nav1.6 of reactive astrocytes in the globus pallidus is closely associated with motor deficits in a model of Parkinson's disease.
Topics: Aged; Animals; Astrocytes; Disease Models, Animal; Globus Pallidus; Mammals; NAV1.6 Voltage-Gated So | 2023 |
Chronic high-sugar diet in adulthood protects Caenorhabditis elegans from 6-OHDA-induced dopaminergic neurodegeneration.
Topics: Adenosine Triphosphate; Animals; Caenorhabditis elegans; Disease Models, Animal; Dopamine; Dopaminer | 2023 |
Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Blood | 2019 |
mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease.
Topics: Animals; Apomorphine; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Neurodegenerative Di | 2020 |
D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induce | 2020 |
Comparison between Tail Suspension Swing Test and Standard Rotation Test in Revealing Early Motor Behavioral Changes and Neurodegeneration in 6-OHDA Hemiparkinsonian Rats.
Topics: Animals; Behavior, Animal; Biomarkers; Case-Control Studies; Corpus Striatum; Disease Models, Animal | 2020 |
Engraftable Induced Pluripotent Stem Cell-Derived Neural Precursors for Brain Repair.
Topics: Animals; Biomarkers; Cell Differentiation; Disease Models, Animal; Dopaminergic Neurons; Heterograft | 2020 |
Oxidative stress in the medullary respiratory neurons contributes to respiratory dysfunction in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Dopaminergic Neurons; Humans; Neurodegenerative Diseases; Oxidative Stress; Oxidopamine; Pa | 2020 |
The protective effects of Ramelteon against 6-OHDA-induced cellular senescence in human SH-SY5Y neuronal cells.
Topics: Aged; Cell Line, Tumor; Cellular Senescence; Humans; Indenes; Neurodegenerative Diseases; Oxidopamin | 2021 |
Neuroprotective effects of coenzyme Q10 in Parkinson's model via a novel Q10/miR-149-5p/MMPs pathway.
Topics: Animals; Disease Models, Animal; Matrix Metalloproteinases; MicroRNAs; Neurodegenerative Diseases; N | 2021 |
Piperine in combination with quercetin halt 6-OHDA induced neurodegeneration in experimental rats: Biochemical and neurochemical evidences.
Topics: Alkaloids; Animals; Benzodioxoles; Brain Chemistry; Disease Models, Animal; Dose-Response Relationsh | 2018 |
Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dop | 2018 |
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease.
Topics: Adenine; Animals; Disease Models, Animal; eIF-2 Kinase; Female; Humans; Indoles; Male; Mice; Mice, I | 2018 |
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopa | 2018 |
Neuroprotective effect of Decalepis hamiltonii aqueous root extract and purified 2-hydroxy-4-methoxy benzaldehyde on 6-OHDA induced neurotoxicity in Caenorhabditis elegans.
Topics: Animals; Apocynaceae; Benzaldehydes; Caenorhabditis elegans; Neurodegenerative Diseases; Neuroprotec | 2018 |
Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration.
Topics: Animals; Circadian Clocks; Dopaminergic Neurons; Mice; Neurodegenerative Diseases; Nuclear Receptor | 2018 |
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progressio | 2019 |
Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
Topics: Adenoviridae; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Gene Expression R | 2013 |
A reliable indirect cell-labelling protocol for optical imaging allows ex vivo visualisation of mesenchymal stem cells after transplantation.
Topics: Adrenergic Agents; Animals; Cells, Cultured; Disease Models, Animal; Flow Cytometry; Humans; Lentivi | 2013 |
Protective effect of INI-0602, a gap junction inhibitor, on dopaminergic neurodegeneration of mice with unilateral 6-hydroxydopamine injection.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Brain-Derived Neurotrophic Factor; Calcium-Binding | 2014 |
Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.
Topics: Animals; Carrier Proteins; Cell Line; Corpus Striatum; Cytokines; Dependovirus; Disease Models, Anim | 2014 |
Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonism.
Topics: Adrenergic Agents; Amitriptyline; Analgesics, Non-Narcotic; Animals; Brain-Derived Neurotrophic Fact | 2015 |
Age and lesion-induced increases of GDNF transgene expression in brain following intracerebral injections of DNA nanoparticles.
Topics: Aging; Animals; Astrocytes; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Genetic Vector | 2015 |
Serum- and Glucocorticoid-Inducible Kinase 1 Confers Protection in Cell-Based and in In Vivo Neurotoxin Models via the c-Jun N-Terminal Kinase Signaling Pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cell Line, Tumor; Dopaminergic Ne | 2015 |
Alpha-linolenic acid suppresses dopaminergic neurodegeneration induced by 6-OHDA in C. elegans.
Topics: Acetylcholinesterase; alpha-Linolenic Acid; Animals; Animals, Genetically Modified; Caenorhabditis e | 2015 |
Sonic Hedgehog Controls the Phenotypic Fate and Therapeutic Efficacy of Grafted Neural Precursor Cells in a Model of Nigrostriatal Neurodegeneration.
Topics: Alkaline Phosphatase; Animals; Animals, Newborn; Disease Models, Animal; Dopaminergic Neurons; Doubl | 2015 |
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Topics: Animals; Benzoxazoles; Disease Models, Animal; Dopamine; Enteric Nervous System; Eosinophils; Gastro | 2016 |
Moderate traumatic brain injury increases the vulnerability to neurotoxicity induced by systemic administration of 6-hydroxydopamine in mice.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Brain; Brain Injuries; Brain Injuries, Traumatic; Co | 2017 |
Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
Topics: Acetaminophen; Adrenergic Agents; alpha-Synuclein; Analgesics, Non-Narcotic; Animals; Animals, Genet | 2008 |
Maternal separation exaggerates the toxic effects of 6-hydroxydopamine in rats: implications for neurodegenerative disorders.
Topics: Animals; Behavior, Animal; Corpus Striatum; Female; Maternal Deprivation; Neurodegenerative Diseases | 2008 |
Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.
Topics: Animals; Benzylamines; Cognition Disorders; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Mal | 2009 |
Minor retinal degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Hallucinations; Haplorhini; Humans; | 2011 |
Dopaminergic neurons of system x(c)⁻-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity.
Topics: Aging; Amino Acid Transport System y+; Animals; Corpus Striatum; Cystine; Dopamine; Glioma; Glutamic | 2011 |
Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Apomorphine; Brain; Cell Differentiation; Ce | 2011 |
Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Animals, Newborn; Arginine; Autoradiography; Cell | 2012 |
Unchanged expression of the ceramide transfer protein in the acute 6-OHDA neurodegenerative model.
Topics: Adrenergic Agents; Animals; Brain; Cell Count; Disease Models, Animal; Gene Expression Regulation; M | 2012 |
Paeonol attenuates microglia-mediated inflammation and oxidative stress-induced neurotoxicity in rat primary microglia and cortical neurons.
Topics: Acetophenones; Animals; Animals, Newborn; Anti-Inflammatory Agents; Cell Survival; Cells, Cultured; | 2012 |
Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidant Respons | 2012 |
L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients.
Topics: Animals; Brain; Dopaminergic Neurons; Humans; Levodopa; Models, Neurological; Neurodegenerative Dise | 2012 |
Insulin-like growth factor-1 inhibits 6-hydroxydopamine-mediated endoplasmic reticulum stress-induced apoptosis via regulation of heme oxygenase-1 and Nrf2 expression in PC12 cells.
Topics: Animals; Antioxidants; Apoptosis; Endoplasmic Reticulum Stress; Heme Oxygenase-1; Humans; Insulin-Li | 2012 |
Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopaminer | 2012 |
Desipramine protects neuronal cell death and induces heme oxygenase-1 expression in Mes23.5 dopaminergic neurons.
Topics: Animals; Antidepressive Agents; Cell Death; Cell Nucleus; Cell Survival; Desipramine; Dopaminergic N | 2012 |
3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzylidene Compounds; Female; Neurodegenerative D | 2013 |
Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion.
Topics: Animals; Indoles; Methylamines; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative D | 2002 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; | 2004 |
Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease.
Topics: Animals; Brain; Female; Lipopolysaccharides; Male; Neurodegenerative Diseases; NG-Nitroarginine Meth | 2005 |
Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Topics: Adrenergic Agents; Aldehydes; alpha-Synuclein; Animals; Behavior, Animal; Blotting, Western; CD11b A | 2005 |
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Topics: Animals; Antioxidants; Cell Survival; Culture Media, Serum-Free; Cysteine; Designer Drugs; Hydroxyl | 2005 |
The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases.
Topics: Activins; Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain; Cell Line, Tumor; Cell Survival; | 2007 |
Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Axotomy; Brain; | 2000 |
Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
Topics: Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Forelimb; Male; Micr | 2001 |
Free 3-nitrotyrosine causes striatal neurodegeneration in vivo.
Topics: Animals; Cell Count; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Immunohistochemistr | 2001 |